NEW YORK, April 10 - Sequenom and Provid Pharmaceuticals today said they plan to co-develop small-molecule therapeutics based on cardiovascular targets discovered by Sequenom.
 
Terms of the deal call for privately held Provid to receive an equity investment and research funding, and to be eligible for milestones and royalties on any products that may arise.

Financial details of the collaboration were not disclosed.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.